Werfen Life Divests to Focus on the Hemostasis Market
The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market. Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175... Read More »December 2016 Didn’t Deliver a Year-End Boost
The final month of the fourth quarter is typically a busy one for deal makers in all industries. Last year, some health care deal makers apparently got a rest. Deal volume in December 2016 was an anemic 119 transactions, compared with 131 deals in November and 148 in December 2015. The Services sectors accounted for 55% of the deals in December, which is on the low side. Consider that, in November, Services accounted for 69% of the month’s transactions, and even 70% of the total in December 2015. Spending on those deals reached $15.4 billion, a relatively modest amount until it is compared with November’s $8.7 billion total (+78%) and December 2015’s $12.3 billion total (+26%). Suddenly,... Read More »Good-Bye, ACA. Now What?
And so it begins. A new year, a new administration, and a foreboding that things can and will go wildly out of control in the healthcare industry, as the new administration dismantles the Affordable Care Act and doesn’t bother to replace it. Judging from the market’s behavior since the November 8 election, the notion that a Hillary Clinton victory was “baked in” to every healthcare deal doesn’t hold. Certainly some deals may have been put on hold following Donald Trump’s election, but 2016 ended with 1,536 deals, in our preliminary count. That’s 1% higher than 2015, which was the first year to break 1,500 transactions. Spending on deals in 2016, while not in record territory, was healthy.... Read More »2016 Delivered on Health Care M and A
As health care mergers and acquisitions go, 2016 lived up to the predictions that M&A activity would stay strong. Preliminary data for year-end totals shows 1,536 announced transactions across 13 healthcare sectors. The total represents a 1% increase in deal volume compared with 2015. (See chart below.) Spending on those deals was significantly lower than the previous year, at least for now. The combined total spending in 2016 now stands at $255.7 billion, down 36% compared with 2015’s $400.3 billion. Nearly $100 billion of that total now hangs in the balance, as two of 2015’s largest deals (Anthem/Cigna and Aetna/Humana) await decisions from a federal judge regarding... Read More »Biotechnology Deals Will Surpass 2015’s Record
Deal volume in the Biotechnology sector is poised to surpass last year’s record-setting 160 transactions. With two weeks left in 2016, deal volume has reached 159 transactions. The activity in this sector shows no signs of abating, and will probably carry through the first half of 2017, at least. Big Pharma companies are driving the M&A activity, as they actively compete for promising drug candidates to bolster their aging pipelines. A case in point is a deal that hasn’t been announced yet, but that the industry is watching with interest. French pharma company Sanofi (NYSE: SNY) is reported to be deep into acquisition talks with Swiss... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
